RNA N6-methyladenosine modification in female reproductive biology and pathophysiology

Erqing Huang, Lijuan Chen
Cell communication and signaling : CCS · 2023 · vol. 21(1) , pp. 53 · doi:10.1186/s12964-023-01078-4 · PMID:36894952 · PMC9996912 · W4323656104
review OA: gold CC0 ⤵ 4 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review summarizes recent findings on N6-methyladenosine modification's roles in female reproductive biology and pathologies, including oogenesis, embryonic development, and gynecological diseases.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

This 2023 review by Huang and Chen surveyed recent evidence on N6-methyladenosine (m6A), the most abundant RNA modification, focusing on its roles in female reproductive biology and disease pathophysiology. It describes how m6A is regulated by “writers,” “erasers,” and “readers” (e.g., METTL3/METTL14/W TAP and others) and summarizes links between m6A-dependent posttranscriptional control and processes such as oogenesis, embryonic/fetal development, and pregnancy complications, while also compiling reported associations with conditions including endometriosis and adenomyosis. The authors note that the precise mechanisms of m6A function remain incompletely elucidated and that effects can be difficult to reconcile because they vary by cell type, environment, RNA features, and intracellular context. This paper is centrally about endometriosis and adenomyosis — it is a broad review that explicitly summarizes m6A involvement in endometriosis and adenomyosis among other female reproductive disorders.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Gene expression and posttranscriptional regulation can be strongly influenced by epigenetic modifications. N6-methyladenosine, the most extensive RNA modification, has been revealed to participate in many human diseases. Recently, the role of RNA epigenetic modifications in the pathophysiological mechanism of female reproductive diseases has been intensively studied. RNA m6A modification is involved in oogenesis, embryonic growth, and foetal development, as well as preeclampsia, miscarriage, endometriosis and adenomyosis, polycystic ovary syndrome, premature ovarian failure, and common gynaecological tumours such as cervical cancer, endometrial cancer, and ovarian cancer. In this review, we provide a summary of the research results of m6A on the female reproductive biology and pathophysiology in recent years and aim to discuss future research directions and clinical applications of m6A-related targets. Hopefully, this review will add to our understanding of the cellular mechanisms, diagnostic biomarkers, and underlying therapeutic strategies of female reproductive system diseases. Video Abstract.

My notes (saved in your browser only)

Condition tags

endometriosisadenomyosis

MeSH descriptors

Abortion, Spontaneous Abortion, Spontaneous Abortion, Spontaneous Abortion, Spontaneous Abortion, Spontaneous Abortion, Spontaneous Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Adenosine Biology

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (100)

Cited by (4)

Source provenance

europepmc
last seen: 2026-06-14T06:08:20.186862+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-06-14T06:07:28.693761+00:00
License: CC0 · commercial use OK